Quintrio
Home

MISCELLANEOUS CHEMICAL PRODUCTS

Cabot Corporation

CBT

Cabot Corp manufactures and sells a variety of chemicals, materials, and chemical-based products. The company organizes itself into the following operating segments based on the product type; the Reinforcement Materials segment which generates maximum revenue provides reinforcing carbon products used in tires, and industrial products such as hoses, belts, extruded profiles, and molded goods; and the Performance Chemicals segment aggregates the specialty carbons, specialty compounds, fumed metal oxides, battery materials, inkjet colorants, and aerogel product lines. Geographically, the company derives maximum revenue from its customers in Europe, the Middle East, and Africa and the rest from the Americas and Asia Pacific region.

Last trade $70.38
Day change -$0.545 (-0.77%)
Day range $70.24 – $71.57
Volume 103,171
Market cap $3.64B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$3.64B
Price / earnings
18.96×
Price / book
2.27×
Price / sales
1×
EV / sales
1.28×
EV / EBITDA
6.93×

Profitability

Earnings per share
$3.74
Return on assets
4.83%
Return on equity
11.96%
Dividend yield
2.66%

Liquidity and leverage

Debt / equity
0.79×
Current ratio
1.47×
Quick ratio
0.97×
Cash ratio
0.22×

Cash flow

Price / cash flow
7.33×
Price / free cash flow
12.96×
Free cash flow
$281M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for CBT, quarterly periods
Line itemQ3 FY2026 Jun 30, 2026Q2 FY2026 Mar 31, 2026Q1 FY2026 Dec 31, 2025Q4 FY2025 Sep 30, 2025Q3 FY2025 Jun 30, 2025Q2 FY2025 Mar 31, 2025Q1 FY2025 Dec 31, 2024Q4 FY2024 Sep 30, 2024
Revenue$982M$904M$849M$899M$923M$936M$955M$1B
Cost of revenue$798M$694M$638M$679M$679M$695M$720M$761M
Gross profit$184M$210M$211M$220M$244M$241M$235M$240M
Selling, general and administrative$73M$67M$69M$68M$62M$64M$66M$73M
Research and development$13M$14M$13M$15M$15M$15M$14M$17M
Total operating expenses$86M$81M$82M$83M$77M$79M$80M$90M
Operating income$98M$129M$129M$137M$167M$162M$155M$150M
Interest expense-$18M-$18M-$18M-$20M-$19M-$19M-$18M-$19M
Income before taxes$60M$120M$118M$115M$156M$151M$144M$135M
Income taxes$46M$44M$37M$63M$43M$49M$41M-$10M
Net income$14M$78M$82M$54M$113M$105M$104M$146M
Net income attributable to common shareholders$6M$67M$72M$47M$101M$92M$92M$140M
EBITDA$148M$178M$170M$177M$206M$200M$192M$187M
Basic earnings per share$0.12$1.27$1.38$0.84$1.87$1.71$1.69$2.41
Diluted earnings per share$0.12$1.27$1.37$0.88$1.86$1.69$1.67$2.52

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Cabot Q4 Earnings Beat on Performance Chemicals Strength

Cabot Corporation reported adjusted Q4 EPS of $1.61, exceeding estimates of $1.55, with revenues rising 12.2% to $1.009 billion. Performance Chemicals EBIT surged 42.9% driven by higher volumes and improved margins, while Reinforcement Materials EBIT declined 26.9% due to lower gross profit per ton despite volume gains. For fiscal 2027, the company projects adjusted earnings of $6.15-$6.75 per share.

Zacks Investment Research

Cabot (CBT) Beats Q4 Earnings and Revenue Estimates

Cabot (CBT) reported quarterly earnings of $1.61 per share, beating consensus estimates of $1.55, with revenues of $1.01 billion exceeding expectations by 6.96%. However, the company received a Zacks Rank #3 (Hold) rating due to mixed estimate revisions. The Chemical - Diversified industry ranks in the bottom 18% of Zacks industries, which could negatively impact future performance.

Zacks Investment Research

DOW Q3 Earnings Beat Estimates on Pricing Gains and Cost Actions

Dow Inc. reported Q3 2026 adjusted EPS of 71 cents, beating consensus estimates, with sales rising 13% to $11.3B. The company's self-help initiatives and higher pricing offset rising input costs. Operating EBITDA reached $1.55B, and Dow remains on track to deliver $700M in transformation benefits in 2026 with approximately $2B total uplift expected by 2027.

Zacks Investment Research

Arkema Expands Shanghai R&D Center to Boost Innovation

Arkema S.A. has officially opened the expansion of its Shanghai R&D Center in China, increasing laboratory space by 20% and adding collaborative facilities including an interactive showroom. The expansion supports the company's focus on high-growth markets including energy, electronics, and mobility through sustainable materials research and development.

Zacks Investment Research

Is NGVT Positioned for Further Adjusted EBITDA Improvement?

Ingevity Corporation (NGVT) reported Q2 adjusted EBITDA of $115 million, up from $101 million year-over-year, driven by higher pricing, favorable product mix, and increased volumes. The company raised its 2026 adjusted EBITDA guidance to $380-$400 million and adjusted EPS outlook to $5-$5.45. NGVT stock has gained 26.3% over the past year and trades at a forward P/S multiple of 2.1, below the industry average of 2.45X.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily
Declared upcoming dividend $0.4725 per share
Declared
Nov 16, 2026
Ex-dividend
Nov 27, 2026
Pay date
Dec 11, 2026
Ex-dividendAmount / sharePay dateType
Aug 28, 2026$0.4725Sep 11, 2026recurring
May 29, 2026$0.4725Jun 12, 2026recurring
Feb 27, 2026$0.45Mar 13, 2026recurring
Nov 28, 2025$0.45Dec 12, 2025recurring
Aug 29, 2025$0.45Sep 11, 2025recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.